+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "GLP-1 Receptor Agonist"

From
From
From
From
From
GLP-1 Agonists Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

GLP-1 Agonists Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Type 2 Diabetes Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Type 2 Diabetes Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
From
From
Type 2 Diabetes Pipeline Analysis Report - Product Thumbnail Image

Type 2 Diabetes Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
Anti-Diabetic Drug Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Anti-Diabetic Drug Market - Forecasts from 2025 to 2030

  • Report
  • January 2025
  • 140 Pages
  • Global
From
From
From
Loading Indicator

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite. GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance. Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more